Multivariate log-linear regression model showing significant predictors of NHL development
| Variable . | . | Incidence NHL per 10 000 patient-years . | Rate ratio4-150 . | 95% CI . | Wald statistics P value . |
|---|---|---|---|---|---|
| Age at entry (y) | >37 | 11.9 | 1.98 | (1.20 to 3.29) | .007 |
| 32-37 | 5.7 | 0.95 | (0.53 to 1.71) | .875 | |
| 27-31 | 8.7 | 1.45 | (0.85 to 2.47) | .178 | |
| ≤26 | 6.0 | 1 | |||
| HAART before | No | 38.7 | 6.44 | (3.79 to 10.96) | <.001 |
| lymphoma | Yes | 6.0 | 1 | ||
| Nadir CD4 count | Missing | 1.0 | 0.17 | (0.07 to 0.42) | <.001 |
| (cells/μL) | ≥291 | 0.2 | 0.03 | (0.01 to 0.13) | <.001 |
| 115-291 | 2.6 | 0.41 | <.001 | ||
| 17-114 | 6.5 | 1.81 | (0.27 to 0.71) | .675 | |
| ≤16 | 6.0 | 1 | (0.75 to 1.56) |
| Variable . | . | Incidence NHL per 10 000 patient-years . | Rate ratio4-150 . | 95% CI . | Wald statistics P value . |
|---|---|---|---|---|---|
| Age at entry (y) | >37 | 11.9 | 1.98 | (1.20 to 3.29) | .007 |
| 32-37 | 5.7 | 0.95 | (0.53 to 1.71) | .875 | |
| 27-31 | 8.7 | 1.45 | (0.85 to 2.47) | .178 | |
| ≤26 | 6.0 | 1 | |||
| HAART before | No | 38.7 | 6.44 | (3.79 to 10.96) | <.001 |
| lymphoma | Yes | 6.0 | 1 | ||
| Nadir CD4 count | Missing | 1.0 | 0.17 | (0.07 to 0.42) | <.001 |
| (cells/μL) | ≥291 | 0.2 | 0.03 | (0.01 to 0.13) | <.001 |
| 115-291 | 2.6 | 0.41 | <.001 | ||
| 17-114 | 6.5 | 1.81 | (0.27 to 0.71) | .675 | |
| ≤16 | 6.0 | 1 | (0.75 to 1.56) |
Abbreviations explained in Table 3.
Adjusted for gender, ethnicity, intravenous drug use, year of entry to study, and other variables in model.